Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
This study has been terminated.
( Slow rates of accrual in North America, enrollment of more than 100 patients in a global study to confirm safe dose. )
Study NCT00272181   Information provided by Viventia Biotech

First Received on January 3, 2006.   Last Updated on September 8, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Carcinoma, Squamous Cell
Neoplasms, Squamous Cell
Head and Neck Neoplasms
Mouth Neoplasms
Head and Neck Cancer
Additional conditions recognized in this trial
Carcinoma
Neoplasms
More general conditions related to this trial
Mouth Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Stomatognathic Diseases
Interventions listed in this trial
Proxinium
Sponsors listed in this trial
Viventia Biotech


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services